HC Wainwright Predicts Higher Earnings for Gain Therapeutics

Gain Therapeutics, Inc. (NASDAQ:GANX) – HC Wainwright lifted their FY2025 EPS estimates for Gain Therapeutics in a research report issued on Monday, December 1st. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.65) per share for the year, up from their previous forecast of ($0.66). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.55) EPS.

Other equities analysts have also issued research reports about the company. Maxim Group raised their target price on Gain Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. BTIG Research restated a “buy” rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, October 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Wednesday, October 8th. Finally, Roth Capital reduced their price target on shares of Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.86.

Gain Therapeutics Trading Up 5.4%

NASDAQ:GANX opened at $3.50 on Wednesday. The company has a market capitalization of $134.61 million, a P/E ratio of -5.74 and a beta of 0.06. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $3.65. The firm has a fifty day simple moving average of $2.32 and a 200-day simple moving average of $1.94.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15).

Hedge Funds Weigh In On Gain Therapeutics

Several institutional investors have recently made changes to their positions in GANX. Wealth Enhancement Advisory Services LLC purchased a new stake in Gain Therapeutics during the third quarter worth $28,000. JPMorgan Chase & Co. purchased a new position in Gain Therapeutics in the third quarter valued at $47,000. Benedict Financial Advisors Inc. raised its position in shares of Gain Therapeutics by 55.6% in the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after acquiring an additional 12,500 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Gain Therapeutics during the 3rd quarter worth about $68,000. Finally, Kovitz Investment Group Partners LLC acquired a new stake in shares of Gain Therapeutics during the 1st quarter valued at about $91,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.